Another preclinical study showed that the IDO inhibitor 1-MT enhanced the efficacy of anti-CTLA-4 and anti-PD-1/PD-L1 treatments by increasing the infiltration and activation of CD8 + T cells at the tumor site [19]. The gene discussed is CTLA4; the disease is neoplasm.